Q-omics provides the consensus-scored TMEM132C profile across patient tissues and cancer cell-line models. TMEM132C expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, TMEM132C is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, TMEM132C RNA expression shows 15,814 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight SCLC, HNSC, and BRCA as cancer lineages where TMEM132C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM132C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM132C survival associations across molecular data types. TMEM132C RNA expression shows survival associations in the most cancer types (29), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM132C RNA expression–survival associations across cancer types. High TMEM132C expression shows unfavorable associations in BLCA, OV and DLBC, but favorable associations in SCLC, HNSC and MESO. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for TMEM132C RNA expression.
This table summarizes TMEM132C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM132C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM132C shows lower tumor expression in HNSC, KIRC, BLCA, LUAD, THCA and STAD. The HNSC box plot shows higher TMEM132C RNA expression in normal versus tumor tissue (log2 FC = −1.638, t-test p < 0.001).
This table shows molecular features associated with TMEM132C in patient tissues and cancer cell lines. In patient samples, TMEM132C shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM132C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC.
